Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTIPROM
2025-520842-31-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ceftriaxone, amoxicillin and azithromycin in Preterm prelabor rupture of membranes (PPROM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite severe perinatal outcome. Planned start Apr 2026; status: authorised.
02
Drugs
ceftriaxoneamoxicillinazithromycin
03
Conditions
Preterm prelabor rupture of membranes (PPROM)
Beyond the preview
Go deeper on 2025-520842-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520842-31-00.